| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.46 | 9e-47 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.45 | 1e-45 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.37 | 7e-35 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.4 | 5e-30 |
| mRNA | Sunitinib | CTRPv2 | pan-cancer | AAC | 0.35 | 3e-27 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.36 | 1e-25 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.45 | 2e-25 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.5 | 5e-25 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | 0.32 | 1e-22 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.32 | 1e-22 |